**Omkar Pharmachem Limited** is an Indian public limited company headquartered in **Ahmedabad, Gujarat**. Listed on the **BSE Limited (Scrip Code: 532167)**, the company is currently undergoing a strategic pivot. Historically a pharmaceutical entity, the company is transitioning through a "business revitalization" phase, seeking to move beyond a period of operational stagnation by diversifying its corporate mandate and exploring new revenue streams within the Indian domestic market. --- ### **Strategic Pivot & Business Revitalization Mandate** The company is currently emerging from a period of limited activity caused by a prior **financial crisis** and a historical **lack of suitable business opportunities**. To address this, management has implemented a recovery strategy focused on three pillars: * **Diversification of Main Objects:** With formal Board and Shareholder approval, the company has amended its **Main Objects clause** in the Memorandum of Association. This allows the company to move beyond its legacy constraints and incorporate **new business activities** designed to get the company "back on track." * **Leadership Continuity:** To ensure stability during this transition, the **Managing Director** has been re-appointed for a second **5-year term** effective **February 14, 2025**. * **Project Acquisition:** Management is actively monitoring **market trends** to secure new **business projects** to expand a revenue base that has remained range-bound for the last three fiscal cycles. --- ### **Operational Infrastructure & Asset Profile** Omkar Pharmachem operates a highly lean, non-capital-intensive model. The company currently maintains no traditional industrial footprint. * **Manufacturing & Real Estate:** The company does **not own or operate any manufacturing plants**. As of **March 31, 2025**, the company held **no immovable property**. * **Asset Management:** While the company carries **Property, Plant, and Equipment (PPE)** and **Intangible Assets** on its balance sheet, these are subject to phased physical verification. No revaluations of PPE or right-of-use assets were conducted in the most recent fiscal year. * **Commodity & FX Exposure:** The business does **not deal in commodities**, eliminating price volatility risks in raw materials. Furthermore, there are no reported **foreign exchange hedging** activities, as operations are currently domestic. --- ### **Financial Performance & Capital Structure** The company’s financial profile is characterized by extreme stability in top-line revenue but a lack of growth, which the current diversification strategy aims to rectify. #### **Three-Year Financial Summary** | Financial Metric (INR in Lacs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **54.22** | **54.35** | **54.30** | | **Profit After Tax (PAT)** | **20.09** | **19.78** | **19.78** | | **Transfer to Reserves** | **Nil** | **Nil** | **Nil** | | **Dividend Recommended** | **Nil** | **Nil** | **Nil** | #### **Equity & Shareholding Data** * **Authorized Capital:** **Rs. 1,050.00 Lacs** (**1,05,00,000 Equity Shares** of **Rs. 10** each). * **Issued & Subscribed Capital:** **1,00,84,800 Equity Shares**. * **Paid-up Capital:** Consists of **1,00,83,300 fully paid-up shares** and **1,500 partly paid-up shares** (Rs. 2.50 each). * **Dematerialization Trends:** There is a gradual shift toward digital holdings. * March 31, 2025: **55.62%** * March 31, 2024: **55.61%** * March 31, 2023: **55.58%** * **Instruments:** The company has **Nil** outstanding GDRs, ADRs, or convertible warrants. --- ### **Liquidity & Solvency Position** The company maintains a low-leverage balance sheet with a focus on internal accruals and debt reduction. | Particulars (₹ in Lakhs) | As at March 31, 2024 | As at March 31, 2023 | | :--- | :--- | :--- | | **Gross Debt (Current Borrowings)** | **30.31** | **62.14** | | **Cash and Cash Equivalents** | **7.16** | **13.27** | | **Adjusted Net Debt** | **23.15** | **48.87** | | **Total Equity** | **923.28** | **904.37** | | **Net Debt to Equity Ratio** | **0.0251** | **0.0540** | --- ### **Risk Management Framework** Management identifies several systemic and operational risks that could impact the success of the revitalization plan: * **Operational Recovery Risk:** The primary risk is the historical inability to sustain active business operations. Success is entirely contingent on the execution of the newly added **business objects**. * **Economic Sensitivity:** The company is highly vulnerable to **slowdowns in the Indian economy** and **global market volatility**, which may impede the acquisition of new projects. * **Credit & Liquidity Risk:** Exposure is limited to **domestic transactions**. The company manages liquidity through **rolling forecasts** and monthly monitoring of receivables to prevent bad debts. * **Market Risk:** The company remains exposed to fluctuations in fair value and cash flows arising from **Interest Rate Risk** and **Equity Price Risk** related to its borrowings and investments. --- ### **Governance & Key Personnel** The company is strengthening its board oversight to ensure strict compliance with **SEBI (LODR) Regulations** and the **Companies Act, 2013**. **Key Managerial Personnel (KMP):** * **Managing Director:** Mr. Bhawani Shankar Goyal (Re-appointed for **5 years** from Feb 2025; Remuneration: **NIL**) * **Chief Financial Officer (CFO):** Mr. Arun Kumar * **Company Secretary & Compliance Officer:** Mr. Shivam Karotiya **Board Oversight:** * **Independent Directors:** Mrs. Mamta Pachauri, Mr. Janak Raj Sharma, and Mr. Anupam Kumar Mishra (Appointed for **5 years** effective Aug 2025). **External Service Providers:** * **Statutory Auditor:** Rajesh J. Shah & Associates * **Registrar & Share Transfer Agent:** Alankit Assignments Limited